These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39147143)

  • 1. Characterization of therapeutic antibody efficacy against multiple SARS-CoV-2 variants in the hamster model.
    Cong Y; Dixit S; Perry DL; Huzella LM; Kollins E; Byrum R; Anthony SM; Drawbaugh D; Lembirik S; Postnikova E; Eaton B; Murphy M; Kocher G; Hadley K; Marketon AE; Bernbaum RM; Hischak AMW; Hart R; Vaughan N; Wada J; Qin J; St Claire MC; Schmaljohn CS; Holbrook MR
    Antiviral Res; 2024 Oct; 230():105987. PubMed ID: 39147143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
    Chen RE; Winkler ES; Case JB; Aziati ID; Bricker TL; Joshi A; Darling TL; Ying B; Errico JM; Shrihari S; VanBlargan LA; Xie X; Gilchuk P; Zost SJ; Droit L; Liu Z; Stumpf S; Wang D; Handley SA; Stine WB; Shi PY; Davis-Gardner ME; Suthar MS; Knight MG; Andino R; Chiu CY; Ellebedy AH; Fremont DH; Whelan SPJ; Crowe JE; Purcell L; Corti D; Boon ACM; Diamond MS
    Nature; 2021 Aug; 596(7870):103-108. PubMed ID: 34153975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.
    Tatham L; Kipar A; Sharp J; Kijak E; Herriott J; Neary M; Box H; Gallardo Toledo E; Valentijn A; Cox H; Pertinez H; Curley P; Arshad U; Rajoli RKR; Rannard S; Stewart JP; Owen A
    Microbiol Spectr; 2024 Aug; 12(8):e0391623. PubMed ID: 39012120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model.
    Abdelnabi R; Foo CS; De Jonghe S; Maes P; Weynand B; Neyts J
    J Infect Dis; 2021 Sep; 224(5):749-753. PubMed ID: 34244768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages.
    Driouich JS; Cochin M; Lingas G; Luciani L; Baronti C; Bernadin O; Gilles M; Villarroel PMS; Moureau G; Petit PR; Dupont A; Izopet J; Kamar N; Autran B; Paintaud G; Caillard S; le Bourgeois A; Richez C; Couzi L; Xhaard A; Marjanovic Z; Avouac J; Jacquet C; Anglicheau D; Cheminant M; Nguyen S; Terrier B; Gottenberg JE; Besson C; Letrou S; Tine J; Basilua JM; Angoulvant D; Tardivon C; Blancho G; Martin-Blondel G; Yazdanpanah Y; Mentré F; Lévy V; Touret F; Guedj J; de Lamballerie X; Nougairède A
    Biomed Pharmacother; 2024 Aug; 177():116988. PubMed ID: 38897157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody cocktail effective against variants of SARS-CoV-2.
    Liang KH; Chiang PY; Ko SH; Chou YC; Lu RM; Lin HT; Chen WY; Lin YL; Tao MH; Jan JT; Wu HC
    J Biomed Sci; 2021 Nov; 28(1):80. PubMed ID: 34814920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
    Park JG; Oladunni FS; Chiem K; Ye C; Pipenbrink M; Moran T; Walter MR; Kobie J; Martinez-Sobrido L
    J Virol Methods; 2021 Jan; 287():113995. PubMed ID: 33068703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
    Bricker TL; Joshi A; Soudani N; Scheaffer SM; Patel N; Guebre-Xabier M; Smith G; Diamond MS; Boon ACM
    J Virol; 2024 Mar; 98(3):e0120623. PubMed ID: 38305154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody drugs targeting SARS-CoV-2: Time for a rethink?
    Liang L; Wang B; Zhang Q; Zhang S; Zhang S
    Biomed Pharmacother; 2024 Jul; 176():116900. PubMed ID: 38861858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
    Uraki R; Kiso M; Iida S; Imai M; Takashita E; Kuroda M; Halfmann PJ; Loeber S; Maemura T; Yamayoshi S; Fujisaki S; Wang Z; Ito M; Ujie M; Iwatsuki-Horimoto K; Furusawa Y; Wright R; Chong Z; Ozono S; Yasuhara A; Ueki H; Sakai-Tagawa Y; Li R; Liu Y; Larson D; Koga M; Tsutsumi T; Adachi E; Saito M; Yamamoto S; Hagihara M; Mitamura K; Sato T; Hojo M; Hattori SI; Maeda K; Valdez R; ; Okuda M; Murakami J; Duong C; Godbole S; Douek DC; Maeda K; Watanabe S; Gordon A; Ohmagari N; Yotsuyanagi H; Diamond MS; Hasegawa H; Mitsuya H; Suzuki T; Kawaoka Y
    Nature; 2022 Jul; 607(7917):119-127. PubMed ID: 35576972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
    Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.
    Phan T; Zitzmann C; Chew KW; Smith DM; Daar ES; Wohl DA; Eron JJ; Currier JS; Hughes MD; Choudhary MC; Deo R; Li JZ; Ribeiro RM; Ke R; Perelson AS;
    PLoS Pathog; 2024 Apr; 20(4):e1011680. PubMed ID: 38635853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants.
    Ishimaru H; Nishimura M; Tjan LH; Sutandhio S; Marini MI; Effendi GB; Shigematsu H; Kato K; Hasegawa N; Aoki K; Kurahashi Y; Furukawa K; Shinohara M; Nakamura T; Arii J; Nagano T; Nakamura S; Sano S; Iwata S; Okamura S; Mori Y
    J Virol; 2023 Jun; 97(6):e0028623. PubMed ID: 37191569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults.
    Cai Y; Diallo S; Rosenthal K; Ren K; Flores DJ; Dippel A; Oganesyan V; van Dyk N; Chen X; Cantu E; Choudhary R; Sulikowski M; Adissu H; Chawla B; Kar S; Liu C; Dijokaite-Guraliuc A; Mongkolsapaya J; Rajan S; Loo YM; Beavon R; Webber C; Chang LJ; Thomas S; Clegg L; Zhang H; Screaton GR; Philbin N; Harre M; Selim A; Martinez-Alier N; Uriel A; Cohen TS; Perez JL; Esser MT; Blair W; Francica JR
    Sci Transl Med; 2024 Jun; 16(753):eado2817. PubMed ID: 38924429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds.
    Schöler L; Le-Trilling VTK; Eilbrecht M; Mennerich D; Anastasiou OE; Krawczyk A; Herrmann A; Dittmer U; Trilling M
    Front Immunol; 2020; 11():573526. PubMed ID: 33162987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters.
    Uraki R; Kiso M; Imai M; Yamayoshi S; Ito M; Fujisaki S; Takashita E; Ujie M; Furusawa Y; Yasuhara A; Iwatsuki-Horimoto K; Sakai-Tagawa Y; Watanabe S; Hasegawa H; Kawaoka Y
    Nat Microbiol; 2022 Aug; 7(8):1252-1258. PubMed ID: 35705860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines.
    Murano K; Guo Y; Siomi H
    Biochem Soc Trans; 2021 Dec; 49(6):2879-2890. PubMed ID: 34854887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.
    Cao X; Maruyama J; Zhou H; Fu Y; Kerwin L; Powers C; Sattler RA; Manning JT; Singh A; Lim R; Healy LD; Johnson S; Paz Cabral E; Li D; Lu L; Ledesma A; Lee D; Richards S; Rivero-Nava L; Li Y; Shen W; Stegman K; Blair B; Urata S; Kishimoto-Urata M; Ko J; Du N; Morais K; Lawrence K; Rivera I; Pai CI; Bresson D; Brunswick M; Zhang Y; Ji H; Paessler S; Allen RD
    Sci Rep; 2022 Sep; 12(1):15517. PubMed ID: 36109550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.